title: What is the role of sofosbuvir in treating hepatitis C infection?
abstract: Sofosbuvir, a nucleotide polymerase inhibitor, was approved in 2013 for treating hepatitis C infection in adults. This article reviews the use of sofosbuvir in combination with ribavirin with or without pegylated interferon.
authors.affiliation: Lawrence Carey is a clinical associate professor in the Temple University School of Pharmacy and a lecturer in pharmacotherapeutics and former program director of the Philadelphia University PA program, both in Philadelphia, Pa. The author has disclosed no potential conflicts of interest, financial or otherwise.
authors.forename: Lawrence
authors.initials: L
authors.lastname: Carey
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D000075202:Contraindications; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons; D000069474:Sofosbuvir